Anti-Human Claudin-18.2 (Zolbetuximab) (C3190-50mg)

CLDN18.2 is a protein that is overexpressed in various cancers, including gastric, pancreatic, and esophageal cancers, making it a valuable therapeutic target. It plays a key role in carcinogenesis, cell polarity, and intercellular adhesion. Monoclonal antibodies like zolbetuximab have shown potential in treating advanced cancers with minimal adverse effects, positioning CLDN18.2 as a promising focus for cancer therapy. A deeper understanding of CLDN18.2's functions is crucial for developing effective treatments, especially for patients with poor prognoses1-3. Zolbetuximab (IMAB362) has demonstrated promise in treating advanced gastric and gastroesophageal junction cancers by targeting CLDN18.2. Clinical trials have shown that Zolbetuximab is well-tolerated and effective, inducing antitumor activity through antibody- dependent cellular cytotoxicity and complement-dependent cytotoxicity. Preclinical studies also support its use in combination with standard chemotherapy, further enhancing its potential as a cancer treatment4-6.